Journal ArticleDOI
Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
Larry K. Kvols,Charles G. Moertel,Michael J. O'Connell,Allan J. Schutt,Joseph Rubin,Richard G. Hahn +5 more
TLDR
It is concluded that SMS 201-995 may be appropriate for use as early therapy in patients with symptoms due to the carcinoid syndrome who have not responded to simpler measures.Abstract:
We studied the effects of a long-acting analogue of somatostatin (SMS 201–995, Sandoz) in 25 patients with histologically proved metastatic carcinoid tumors and the carcinoid syndrome. Thi...read more
Citations
More filters
Journal ArticleDOI
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
Jonathan R. Strosberg,Ghassan El-Haddad,Edward M. Wolin,Andrew Eugene Hendifar,James C. Yao,Beth Chasen,Erik Mittra,Pamela L. Kunz,Matthew H. Kulke,Heather A. Jacene,David L. Bushnell,Thomas M. O'Dorisio,Richard A. Baum,Harshad R. Kulkarni,Martyn Caplin,Rachida Lebtahi,Timothy J. Hobday,Ebrahim S. Delpassand,E. Van Cutsem,Al B. Benson,Raj Srirajaskanthan,Marianne Pavel,J. Mora,Jordan Berlin,Enrique Grande,N. Reed,Ettore Seregni,Kjell Öberg,M. Lopera Sierra,P. Santoro,Thomas Thevenet,Jack L. Erion,Philippe Ruszniewski,Dirk Jan Kwekkeboom,E.P. Krenning +34 more
TL;DR: Treatment with lutetium‐177 (177Lu)–Dotatate resulted in markedly longer progression‐free survival and a significantly higher response rate than high‐dose octreotide LAR among patients with advanced midgut neuroendocrine tumors.
Journal ArticleDOI
Clinical practice guidelines in oncology
William J. Gradishar,Benjamin O. Anderson,Ron Balassanian,Sarah L. Blair,Harold J. Burstein,Amy E. Cyr,Anthony D. Elias,William B. Farrar,Andres Forero,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Janice A. Lyons,P. Kelly Marcom,Ingrid A. Mayer,Beryl McCormick,Meena S. Moran,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Elizabeth C. Reed,Kilian E. Salerno,Lee S. Schwartzberg,Amy Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,George Somlo,Melinda L. Telli,John H. Ward,Rashmi Kumar,Dorothy A. Shead +32 more
TL;DR: This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
Journal ArticleDOI
Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system
TL;DR: The observation of elevation of substance P—like and CGRP‐like immunoreactivity after activation of the nociceptive afferent system of the head provides new insights into a putative role of peptides in the pathophysiology of migraine and cluster headache, and suggests new areas of possible therapeutic intervention.
Journal ArticleDOI
Current status of gastrointestinal carcinoids.
TL;DR: Gastrointestinal carcinoids are ill-understood, enigmatic malignancies, which, although slow growing compared with adenocarcinomas, can behave aggressively and require surgery to avert local manifestations and decrease hormone secretion.
Journal ArticleDOI
Peptidomimetics for Receptor Ligands—Discovery, Development, and Medical Perspectives
TL;DR: Peptidomimetics, compounds that act as substitutes for peptides in their interaction with receptors, have been synthesized and show higher metabolic stability, better bioavailability, and longer duration of action.
References
More filters
Journal ArticleDOI
SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.
TL;DR: The analogue H-(D) Phe-Cys-Phe-( D) Trp-Lys-Thr-CYS-ThR(ol) code-named SMS 201-995, which in vitro is three times more potent than the native hormone in inhibiting the secretion of growth hormone, is well tolerated both in laboratory animals and in man.
Journal Article
Somatostatin (First of two parts)
TL;DR: Phylogenie de la somatostatine, biosynthese, manipulation et transport, fonction dans the regulation hypophysaire.
Journal ArticleDOI
Letter: HL-A antigens in myasthenia gravis.
Journal ArticleDOI
Treatment of the carcinoid tumor and the malignant carcinoid syndrome.
TL;DR: The carcinoid syndrome presents an unparalleled opportunity for fundamental physiologic observations and for experimental therapeutic study that can have applicability not only in palliating the syndrome itself but also in the management of other pathophysiologic states that may involve more subtle abnormalities of the same hormonal mechanisms.
Journal ArticleDOI
Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases.
TL;DR: A 43-yr-old-man with metastatic VIPoma who was treated with a new long-acting somatostatin analogue for 14 mo, SMS 201-995 not only controlled the diarrhea without side effects but appeared to have possibly induced a reduction in metastatic tumor size.